These studies are based on internal data modeling, early lab results, or known compound behaviors. Transparency annotations are included for clarity.
Status: Internal Model - Human Trials Not Yet Initiated
Cu²⁺-Histidine showed ROS-scavenging behavior in oxidative stress models. Simulated timed release in redox-shifting environments correlated with inflammation resolution markers. In vivo validation pending.
Status: Confirmed pH Activation in vitro
Using artificial tumor microenvironments, Ru⁴⁺-Doxorubicin remained inactive in normal pH but triggered cell death in acidic chambers. Current effort focuses on tumor-specific uptake models.